Fischer Medical Ventures Limited (FMVL) has reaffirmed its strategic partnership with Nanyang Biologics (NYB), underscoring its commitment to bringing advanced artificial intelligence (AI)-powered molecular research technologies to India and supporting the country's pharmaceutical and life sciences ecosystem.

As part of the collaboration, Fischer Medical Ventures plans to introduce AI-enabled molecular research capabilities in India while fostering collaborations with pharmaceutical companies, biotechnology firms, academic institutions and research organisations. 

The partnership seeks to accelerate the discovery of novel therapeutic molecules by combining AI with India's scientific expertise and botanical heritage, subject to scientific validation and regulatory approvals.

Under the agreement, Fischer Medical Ventures will serve as the exclusive distributor in India for selected Nanyang Biologics technologies and scientifically developed plant-based nutraceutical products, subject to applicable regulatory approvals.

A key component of the collaboration is Vecura, Nanyang Biologics' AI-driven molecular research platform, which enables researchers to simulate molecular behaviour, predict material properties and conduct high-throughput computational analysis, helping accelerate research and therapeutic discovery.

Ravindran Govindan, Chairman of Fischer Medical Ventures Limited, said, "We are proud to work alongside an organisation that is helping redefine AI-driven molecular research, and we look forward to introducing these capabilities to India's scientific and pharmaceutical community," he said.

Govindan added: "By combining these strengths with advanced artificial intelligence, we have an opportunity to accelerate innovation, strengthen research capabilities and contribute to the discovery of new therapies that address unmet medical needs,"he noted.

Svetlana Rao Raviwada, Whole-Time Executive Director of Fischer Medical Ventures Limited, said, "Our partnership with Nanyang Biologics is about more than bringing advanced technology to India; it is about building an AI-enabled life sciences ecosystem that strengthens collaboration between academia, research institutions and the pharmaceutical industry."